Assignee
EXUMA BIOTECH CORP
US·7 granted patents·13 pending applications·21 citations·filing 2017–2025
Top patents by PatentIndex Score
20 records- 0193US11325948B2Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPLEXUMA BIOTECH CORP·Filed 2020·Granted May 10, 2022·6 cites·27 claims
- 0292US12258574B2Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2023·Granted Mar 25, 2025·1 cites·26 claims
- 0392US10596274B2Methods and compositions for transducing lymphocytes and regulated expansion thereofEXUMA BIOTECH CORP·Filed 2017·Granted Mar 24, 2020·10 cites·24 claims
- 0488US11111505B2Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2017·Granted Sep 7, 2021·3 cites·21 claims
- 0587US12325728B2Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of CD79A and CD79BEXUMA BIOTECH CORP·Filed 2022·Granted Jun 10, 2025·1 cites·26 claims
- 0680US2023257776A1Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2023·Application pending·0 cites
- 0777US2025236889A1Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2025·Application pending·0 cites
- 0876US2025026840A1Chimeric antigen receptors against axl or ror2 and methods of use thereofEXUMA BIOTECH CORP·Filed 2024·Application pending·0 cites
- 0973US2021403952A1Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2021·Application pending·0 cites
- 1066US2025099612A1Viral particles with membrane-bound hyaluronidaseEXUMA BIOTECH CORP·Filed 2023·Application pending·0 cites
- 1162US2023392139A1Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2023·Application pending·0 cites
- 1257US12187801B2Chimeric antigen receptors against AXL or ROR2 and methods of use thereofEXUMA BIOTECH CORP·Filed 2018·Granted Jan 7, 2025·0 cites·22 claims
- 1357US2023357436A1Anti-idiotype compositions and methods of use thereofEXUMA BIOTECH CORP·Filed 2021·Application pending·0 cites
- 1456US2023044451A1Methods and compositions for the delivery of modified lymphocytes and/or retroviral particlesEXUMA BIOTECH CORP·Filed 2022·Application pending·0 cites
- 1554US2023072955A1Chimeric antigen receptors to her2 and methods of use thereofEXUMA BIOTECH CORP·Filed 2021·Application pending·0 cites
- 1652US12590321B2Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2020·Granted Mar 31, 2026·0 cites·21 claims
- 1751US2023111159A1Methods and compositions for the delivery of modified lymphocyte aggregatesEXUMA BIOTECH CORP·Filed 2021·Application pending·0 cites
- 1850US2022340927A1Methods and compositions for the modification and delivery of lymphocytesEXUMA BIOTECH CORP·Filed 2020·Application pending·0 cites
- 1950US2021317408A1Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcsEXUMA BIOTECH CORP·Filed 2019·Application pending·0 cites
- 2045US2020397821A1Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EXUMA BIOTECH CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →